Cardiogenesis (Irvine, California) continues to move forward with its plans to initiate a safety and feasibility trial for its Phoenix system in patients with refractory angina. The company said it has submitted an investigational device exemption (IDE) to the FDA to initiate the trial. (Medical Device Daily)